Skip to the page

Data / Drug companies / Afaxys Pharma, LLC

Afaxys Pharma, LLC: 11 products in the FDA NDC directory, labeler code 50102

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Afaxys Pharma, LLC (labeler code 50102) lists 11 products in the FDA National Drug Code Directory, covering 6 finished drugs by generic name. By type: 10 prescription drugs, 1 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on February 27, 2018.

The request: Watch Afaxys Pharma, LLC (FDA labeler code 50102): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
50102
Products in commercial distribution
11
Packages
13
Finished drugs by generic name
6
Prescription products
10
Over the counter products
1
Flagged as original packager
11 of 11 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
July 6, 2016
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)11100%

Products by type

TypeProductsShare
Prescription drugs1090.9%
Over the counter drugs19.1%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Kit981.8%
Tablet218.2%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Jasmiel50102-240KitGeneric drugs (ANDA)February 27, 2018
EContra One-Step50102-211TabletGeneric drugs (ANDA)February 8, 2018
Tarina Fe 1/20 EQ50102-228KitGeneric drugs (ANDA)June 16, 2017
Tarina 24 fe50102-224KitGeneric drugs (ANDA)June 15, 2017
Cyred EQ50102-254KitGeneric drugs (ANDA)May 17, 2017
Aubra EQ50102-220KitGeneric drugs (ANDA)November 14, 2016
Tri-VyLibra Lo50102-231KitGeneric drugs (ANDA)November 4, 2016
Lyleq50102-300TabletGeneric drugs (ANDA)September 23, 2016
Chateal EQ50102-230KitGeneric drugs (ANDA)September 23, 2016
VyLibra50102-235KitGeneric drugs (ANDA)July 7, 2016
Tri-VyLibra50102-233KitGeneric drugs (ANDA)July 6, 2016

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.